Compare BAK & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAK | KMDA |
|---|---|---|
| Founded | 1972 | 1990 |
| Country | Brazil | Israel |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.3M | 460.3M |
| IPO Year | 2002 | 2013 |
| Metric | BAK | KMDA |
|---|---|---|
| Price | $0.75 | $7.76 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $1.33 | ★ $13.75 |
| AVG Volume (30 Days) | ★ 3.1M | 110.2K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 7.15% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.86 | $12.75 |
| Revenue Next Year | $5.37 | $13.63 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $6.63 |
| 52 Week High | $5.40 | $9.35 |
| Indicator | BAK | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 24.96 | 47.71 |
| Support Level | $0.74 | $6.91 |
| Resistance Level | $1.20 | $8.16 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 1.56 | 63.92 |
Braskem SA is engaged in the manufacture, sale, import and export of chemicals, petrochemicals and fuels, as well as the production, supply and sale of utilities such as steam, water, compressed air and industrial gases. It also provides industrial services and is engaged in the production, supply and sale of electric energy and gas for its own use and use by other companies. Its segments include Brazil, USA and Europe; and Mexico. The Brazil segments delivered the majority of the revenue from the production and sale of chemicals; the supply of electricity and other inputs produced in these complexes to second-generation producers located in the petrochemical complexes; and the production and sale of PE, including the production of green PE made from renewable resources, and of PP.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.